Literature DB >> 31032288

Blocking the PD-1/PD-L1 axis in advanced prostate cancer: are we moving in the right direction?

Andre P Fay1,2, Emmanuel S Antonarakis3,4.   

Abstract

Entities:  

Year:  2019        PMID: 31032288      PMCID: PMC6462610          DOI: 10.21037/atm.2019.01.37

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  28 in total

1.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Journal:  N Engl J Med       Date:  2010-07-29       Impact factor: 91.245

2.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

3.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

5.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

6.  Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.

Authors:  S F Slovin; C S Higano; O Hamid; S Tejwani; A Harzstark; J J Alumkal; H I Scher; K Chin; P Gagnier; M B McHenry; T M Beer
Journal:  Ann Oncol       Date:  2013-03-27       Impact factor: 32.976

7.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  Alpha emitter radium-223 and survival in metastatic prostate cancer.

Authors:  C Parker; S Nilsson; D Heinrich; S I Helle; J M O'Sullivan; S D Fosså; A Chodacki; P Wiechno; J Logue; M Seke; A Widmark; D C Johannessen; P Hoskin; D Bottomley; N D James; A Solberg; I Syndikus; J Kliment; S Wedel; S Boehmer; M Dall'Oglio; L Franzén; R Coleman; N J Vogelzang; C G O'Bryan-Tear; K Staudacher; J Garcia-Vargas; M Shan; Ø S Bruland; O Sartor
Journal:  N Engl J Med       Date:  2013-07-18       Impact factor: 91.245

Review 9.  CTLA-4: new insights into its biological function and use in tumor immunotherapy.

Authors:  Jackson G Egen; Michael S Kuhns; James P Allison
Journal:  Nat Immunol       Date:  2002-07       Impact factor: 25.606

10.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Authors:  Yoshiko Iwai; Masayoshi Ishida; Yoshimasa Tanaka; Taku Okazaki; Tasuku Honjo; Nagahiro Minato
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-06       Impact factor: 11.205

View more
  9 in total

1.  Using nanoparticles for in situ vaccination against cancer: mechanisms and immunotherapy benefits.

Authors:  Michael-Joseph Gorbet; Akansha Singh; Chenkai Mao; Steven Fiering; Ashish Ranjan
Journal:  Int J Hyperthermia       Date:  2020-12       Impact factor: 3.914

Review 2.  Tumour mutational burden: primary versus metastatic tissue creates systematic bias.

Authors:  Desiree Schnidrig; Samra Turajlic; Kevin Litchfield
Journal:  Immunooncol Technol       Date:  2019-12-16

3.  Comprehensive analysis of alternative splicing profiling reveals novel events associated with prognosis and the infiltration of immune cells in prostate cancer.

Authors:  Tianqi Wu; Wenfeng Wang; Yanhao Wang; Mengfei Yao; Leilei Du; Xingming Zhang; Yongqiang Huang; Jianhua Wang; Hongbo Yu; Xiaojie Bian
Journal:  Transl Androl Urol       Date:  2021-07

4.  Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma.

Authors:  Richard F Schlenk; Gundram Jung; Helmut R Salih; Jonas S Heitmann; Juliane S Walz; Martin Pflügler; Joseph Kauer
Journal:  BMJ Open       Date:  2020-10-16       Impact factor: 2.692

5.  Endoplasmic reticulum oxidoreductase 1 alpha modulates prostate cancer hallmarks.

Authors:  Julian Cornelius; Ilaria Cavarretta; Edoardo Pozzi; Giovanni Lavorgna; Irene Locatelli; Tiziana Tempio; Francesco Montorsi; Agostino Mattei; Roberto Sitia; Andrea Salonia; Tiziana Anelli
Journal:  Transl Androl Urol       Date:  2021-03

6.  A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells.

Authors:  Maria E Lund; Christopher B Howard; Kristofer J Thurecht; Douglas H Campbell; Stephen M Mahler; Bradley J Walsh
Journal:  BMC Cancer       Date:  2020-12-10       Impact factor: 4.430

7.  Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model.

Authors:  Nourridine Siewe; Avner Friedman
Journal:  PLoS One       Date:  2022-01-11       Impact factor: 3.240

Review 8.  BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations.

Authors:  Sidrah Shah; Rachelle Rachmat; Synthia Enyioma; Aruni Ghose; Antonios Revythis; Stergios Boussios
Journal:  Int J Mol Sci       Date:  2021-11-23       Impact factor: 5.923

Review 9.  What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes.

Authors:  Andrea Palicelli; Stefania Croci; Alessandra Bisagni; Eleonora Zanetti; Dario De Biase; Beatrice Melli; Francesca Sanguedolce; Moira Ragazzi; Magda Zanelli; Alcides Chaux; Sofia Cañete-Portillo; Maria Paola Bonasoni; Stefano Ascani; Antonio De Leo; Guido Giordano; Matteo Landriscina; Giuseppe Carrieri; Luigi Cormio; Jatin Gandhi; Davide Nicoli; Enrico Farnetti; Simonetta Piana; Alessandro Tafuni; Martina Bonacini
Journal:  Biomedicines       Date:  2022-01-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.